Physician profile
William D Lorenz
NPI 1376595660
$66,105.32
in general payments reported to CMS, 2019-2025
17 companies · $5,793 in 2025
The $5,793 reported for 2025 was more than what 97% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,798 · 2021: $15K · 2022: $13K · 2023: $5,097 · 2024: $11K · 2025: $5,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Travel and Lodging: $1,998 · Food and Beverage: $1,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,787.50 |
| Travel and Lodging | $1,997.60 |
| Food and Beverage | $1,905.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $33,230.05 | 2019-2022 | |
| Abbvie INC. | $31,015.27 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $293.51 | 2019-2025 | Dysport |
| Saol Therapeutics INC. | $275.85 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $270.39 | 2021-2025 | Xeomin |
| Janssen Pharmaceuticals, INC | $255.39 | 2020-2024 | Xarelto |
| Amneal Pharmaceuticals LLC | $197.95 | 2022-2025 | Lioresal (Baclofen), Lyvispah |
| Mdd US Operations, LLC | $162.67 | 2019-2020 | |
| Tersera Therapeutics LLC | $139.70 | 2019-2021 | |
| Merz North America, INC. | $111.98 | 2019-2020 | |
| Pfizer INC. | $42.72 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $27.96 | 2021 | |
| Flowonix Medical Incorporated | $22.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.73 | 2019 | |
| Lundbeck LLC | $16.42 | 2024 | Vyepti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $13.83 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lorenz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.